Theralase Technologies — Fact Sheet (October 2024)

2 slides from Theralase Technologies's fact sheet, October 2024

Slide 1: Next Standard of Care for Bladder Cancer
TSXV:TLT | OTCQB:TLTFF Next Standard of Care for Bladder Cancer There Exists a Critical Need for Effective Bladder-Sparing Therapies Theralase® is Trending to be Safer and More Effective than All Currently Approved FDA Drugs
Slide 2: Pre-Breakthrough Designation Submission and Swimmer's Plot
In response to this latest clinical data, Theralase® has submitted a pre-Break Through Designation (“BTD”) submission to the FDA The Swimmer’s Plot below graphically displays the assessment of each patient who achieved a CR or IR response. www.theralase.com/invest/ 2 Toll Free: 1-866-843-5273 X229